A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Status:
Completed

Trial end date:
2021-05-26

Target enrollment:

Participant gender:

This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.

Phase 1

Jazz Pharmaceuticals